BR112023022705A2 - Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares - Google Patents

Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Info

Publication number
BR112023022705A2
BR112023022705A2 BR112023022705A BR112023022705A BR112023022705A2 BR 112023022705 A2 BR112023022705 A2 BR 112023022705A2 BR 112023022705 A BR112023022705 A BR 112023022705A BR 112023022705 A BR112023022705 A BR 112023022705A BR 112023022705 A2 BR112023022705 A2 BR 112023022705A2
Authority
BR
Brazil
Prior art keywords
intravitrual
treatment
pharmaceutical compositions
drug delivery
delivery systems
Prior art date
Application number
BR112023022705A
Other languages
English (en)
Portuguese (pt)
Inventor
Dawn Glendenning Angela
Cheng-Wen Lin
Sevgi Gurkan
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Publication of BR112023022705A2 publication Critical patent/BR112023022705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023022705A 2021-04-30 2022-04-29 Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares BR112023022705A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182559P 2021-04-30 2021-04-30
US202163287737P 2021-12-09 2021-12-09
PCT/US2022/027048 WO2022232588A1 (en) 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
BR112023022705A2 true BR112023022705A2 (pt) 2024-01-16

Family

ID=83848732

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022705A BR112023022705A2 (pt) 2021-04-30 2022-04-29 Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Country Status (10)

Country Link
US (2) US11786510B2 (enExample)
EP (1) EP4329753A4 (enExample)
JP (1) JP2024515826A (enExample)
KR (1) KR20240004643A (enExample)
AU (1) AU2022264036A1 (enExample)
BR (1) BR112023022705A2 (enExample)
CA (1) CA3218251A1 (enExample)
IL (1) IL307997A (enExample)
MX (1) MX2023012723A (enExample)
WO (1) WO2022232588A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4050997A4 (en) 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3218398A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
WO2025137005A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases
WO2025137007A1 (en) * 2023-12-20 2025-06-26 Perfuse Therapeutics, Inc. Methods of preparing drug delivery systems for the treatment of ocular diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
JP2004525890A (ja) 2001-02-02 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR20130050939A (ko) 2010-04-12 2013-05-16 가부시키가이샤 아루떼꾸 우에노 망막 질환의 치료 방법 및 이를 위한 안과용 조성물
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
PT3062775T (pt) 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
MX390909B (es) 2013-12-19 2025-03-21 Tassos Georgiou Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CN107921036A (zh) * 2015-05-29 2018-04-17 优势医疗公司 用于减少视力丧失的组合物和方法
CN108883070A (zh) 2015-07-23 2018-11-23 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン，キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
KR20210135560A (ko) 2019-03-05 2021-11-15 에어리 파마슈티컬즈, 인코포레이티드 안구 질환 또는 장애를 치료하는 약학 조성물
EP4050997A4 (en) 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329753A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
CA3218398A1 (en) * 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists

Also Published As

Publication number Publication date
JP2024515826A (ja) 2024-04-10
IL307997A (en) 2023-12-01
MX2023012723A (es) 2024-02-08
AU2022264036A1 (en) 2023-11-23
US20230414577A1 (en) 2023-12-28
KR20240004643A (ko) 2024-01-11
US11786510B2 (en) 2023-10-17
EP4329753A1 (en) 2024-03-06
WO2022232588A1 (en) 2022-11-03
US20230105507A1 (en) 2023-04-06
EP4329753A4 (en) 2025-02-26
CA3218251A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
BR112023022705A2 (pt) Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CA2909160C (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
AR068816A1 (es) Composiciones de brimonidina mejorada para el tratamiento del eritema
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
van der Merwe et al. Endophthalmitis prophylaxis with intracameral cefuroxime in South Africa
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
MX2023005533A (es) Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.
KR20190120197A (ko) 치료 및 신경보호 펩티드
US10279046B2 (en) Eye drop composition for treating ocular inflammatory disease and preparation method therefor
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
CN101332180A (zh) 霉酚酸滴眼剂及其制备方法
RU2545798C1 (ru) Фармацевтическая композиция для оказания первой медицинской помощи при ожогах различной этиологии, площади и глубины в форме спрея, геля, аэрозоля
ZA202106768B (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
RU2416394C1 (ru) Фармацевтическая композиция в виде спрея для лечения раневых поверхностей
CA3113929C (en) Use of miltefosine for treating free-living amoebic infections
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
US20200316075A1 (en) Ganciclovir compositions and related methods
AR077458A1 (es) Composiciones de copolimero en bloque de oxido de etileno oxido de butileno
BR112022001620A2 (pt) Composto, processo para preparar um composto, composição farmacêutica e conjugado anticorpo-droga
RU2475248C1 (ru) Офтальмологическое средство-2 для кросслинкинга
CN116251169A (zh) 达托霉素滴眼液、其制备方法及应用
BR112023021049A2 (pt) Uso de adenina na fabricação de um medicamento para tratamento de úlcera diabética
BR112023020273A2 (pt) Novos compostos heterocíclicos e seus usos
RU2419417C1 (ru) Фармацевтическая композиция в виде раствора флуконазола, обладающая противогрибковым действием
RU2008126108A (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту